Bellevue Group Ag Cure Vac N.V. Transaction History

Bellevue Group Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$33.72 - $48.22 $1.19 Million - $1.7 Million	-35,200 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$49.26 - $74.5 $310,338 - $469,350	6,300 Added 21.8%	35,200 $1.92 Million
Q1 2021 May 12, 2021	BUY	$79.79 - $126.29 $949,501 - $1.5 Million	11,900 Added 70.0%	28,900 $2.64 Million
Q4 2020 Feb 16, 2021	SELL	$46.76 - $136.27 $1.57 Million - $4.57 Million	-33,500 Reduced 66.34%	17,000 $1.38 Million
Q3 2020 Nov 16, 2020	BUY	$43.8 - $77.2 $2.21 Million - $3.9 Million	50,500 New	50,500 $2.35 Million

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $514M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.